Document Type
Article
Publication Date
2017
Abstract
The Broad Institute's recent licensing of its gene editing patent portfolio demonstrates how licenses can be used to restrict controversial applications of emerging technologies while society deliberates their implications.
Recommended Citation
NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 1 JANUARY 2017
Included in
Antitrust and Trade Regulation Commons, Health Law and Policy Commons, Intellectual Property Law Commons, Science and Technology Law Commons
Comments
35 Nature Biotechnology 22 (2017)